Jones Trading analyst Debanjana Chatterjee maintains Contineum Therapeutics (NASDAQ:CTNM) with a

Analysts downgraded CTNM, CC, ACI, BRKR and SAFE; targets fell for CTNM, CC and ACI, while BRKR rece

Baird analyst Joel Beatty downgrades Contineum Therapeutics (NASDAQ:CTNM) from Outperform to Neut

Gainers Mobile-health Network (NASDAQ:MNDR) stock rose 370.0% to $4.0 during Monday's regular s

Contineum Therapeutics, Inc. (CTNM) might move higher on growing optimism about its earnings prospec

Contineum Therapeutics Inc. (NASDAQ:CTNM) stock plunged Monday following mixed Phase 3 trial results

BMS trial results trigger a 29% drop in Contineum (CTNM), but analysts highlight long-term potential

Gainers Mobile-health Network (NASDAQ:MNDR) shares increased by 141.2% to $2.05 during Monday's

U.S. stocks rose as Nasdaq gained 100+ points; HPE jumped 5.1% on stronger networking guidance and a

Morgan Stanley analyst Jeffrey Hung maintains Contineum Therapeutics (NASDAQ:CTNM) with a Equal-W

Squarepoint Ops LLC lessened its position in shares of Contineum Therapeutics, Inc. (NASDAQ: CTNM) b

Shares of Contineum Therapeutics, Inc. (NASDAQ: CTNM - Get Free Report) dropped 9.9% during mid-day

Contineum Therapeutics, Inc. (NASDAQ:CTNM) shares are trading lower on Tuesday as Phase 2 results fr

Contineum Therapeutics shares fall as Phase 2 MOONLIGHT-1 depression trial fails primary endpoint. P

Baird analyst Joel Beatty maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and lo

Kestra Medical fell 8.6% after missing earnings estimates despite beating sales forecasts; several o

Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpointAnalyses of the data, including

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),

Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.9% to $0.17 during Thursday's

RBC Capital analyst Brian Abrahams maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperfo

Contineum has streamlined its discovery programs to focus on drug candidates for the treatment of in

Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.40) per share which beat the a

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),

Does Contineum Therapeutics, Inc. (CTNM) have what it takes to be a top stock pick for momentum inve

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmace

- Manuscript describes the discovery of LPAR1 antagonist PIPE-791, now in a Phase 2 clinical trial f

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),

The consensus price target hints at a 60% upside potential for Contineum Therapeutics, Inc. (CTNM).

Contineum Therapeutics NASDAQ: CTNM President and Chief Executive Officer Carmine Stengone said the

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),

Morgan Stanley analyst Jeffrey Hung maintains Contineum Therapeutics (NASDAQ:CTNM) with a Equal-W

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),

The average of price targets set by Wall Street analysts indicates a potential upside of 49.2% in Co

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company),